Regeneron antibody cuts risk of COVID-19 death in UK study

Dive Brief: A major study found that Regeneron’s antibody treatment can reduce the risk of death for certain people hospitalized with COVID-19, the first definitive evidence a drug aimed at the coronavirus can lower mortality among the sickest patients.   Regeneron’s combination antibody regimen cut the risk of death by 20% in patients who had […]

Trial failure dashes Biogen hopes for next Alzheimer’s drug

Dive Brief: An experimental Alzheimer’s disease treatment developed by Biogen didn’t slow patients’ decline when compared to a placebo in a mid-stage study, leading the Massachusetts-based biotech to halt all work on the drug. Known as gosuranemab, the drug blocks a protein that accumulates in patients’ brain called tau, which is different than the way […]

Asia—Biogen, Eisai’s Alzheimer’s nod; Stemirna’s $188M mRNA vaccine raise; China-made HER2 ADC

Biogen and partner Eisai’s aducanumab have won a landmark—yet widely criticized—FDA approval for Alzheimer’s disease drug Aduhelm, and the companies are eying a big potential market in Asia. China’s Stemirna Therapeutics raised $188 million for its mRNA COVID-19 vaccine ambitions. Chinese authorities have cleared a homegrown HER2-targeted antibody-drug conjugate by RemeGen for stomach cancer. And more. 1. Biogen’s aducanumab crosses FDA […]